Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Alexander (Sandy) Douglas

Alexander (Sandy) Douglas

Alexander (Sandy) Douglas

DPhil, MRCP, DipPharmMed

Research Group Leader

I am a pharmaceutical physician and Wellcome Trust Career Development Fellow. 

My main interests are the development of new antibody-inducing vaccines and breaking down the barriers to translation of new biological medicines into clinical trials. My group's work spans from protein biochemistry and virology (seeking to design new and improved vaccine antigens), through development of high-quality yet cost-effective biological manufacturing processes, to clinical trials. 


My group led manufacturing scale-up of the University of Oxford COVID-19 vaccine candidate up to the point of transfer to AstraZeneca. This included the development of a novel and highly cost-effective large-scale manufacturing process, which is now underpinning global supply of the vaccine. 

I am a Co-Investigator on the EPSRC funded Future Vaccine Manufacturing Research Hub (Vax-Hub) 


Existing rabies vaccines require multiple doses, cold-chain storage and are moderately expensive: as a result they are not widely used in rabies-endemic areas, and 50,000 people die of rabies every year. I have developed and am leading clinical trials of an adenovirus-vectored rabies vaccine which aims to provide a cheap, single-dose tool suitable for mass pre-exposure rabies prophylaxis. This work is funded by an MRC DPFS award.

I have also recently received funding from the Wellcome Trust for a new project investigating the feasibility of development of a vaccine against Epstein Barr virus. Although most people are infected with EBV without suffering serious effects, it causes a substantial burden of cancers and may drive development of certain immune-mediated diseases, such as multiple sclerosis. 


I previously identified the potential of PfRH5 as an antigen capable of inducing highly potent strain-transcending neutralising antibodies against the Plasmodium falciparum blood-stage and demonstrated that PfRH5-based vaccines could achieve in vivo protection against a virulent P. falciparum challenge. These vaccines are now in clinical trials.

PfRH5 was identified by investigating the mechanism of erythrocyte invasion by P. falciparum merozoites. Sporozoites are in many ways more attractive vaccine targets than merozoites, but understanding of the mechanism of sporozoite invasion into hepatocytes is poor. I am seeking to identify sporozoite ligands and host receptors required for this invasion process, with the aim of developing interventions to prevent infection by disrupting their interactions.